Amount of qualified sufferers: CDEC talked about the uncertainty in the amount of individuals with moderately intense to intense hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or average disorder could have a extreme https://hemgenix73998.blogofoto.com/66918730/the-definitive-guide-to-hemgenix